CADL Stock Soars as Phase III Prostate Cancer Study Meets Primary Goal

Shares of Candel Therapeutics (CADL) surged 68.1% on Wednesday after the company reported superior efficacy of CAN-2409, an investigational adenovirus immunotherapy candidate, compared to standard of care (SOC) radiation therapy alone in a late-stage study to treat prostate cancer.The phase III study enrolled intermediate-to-high-risk, localized prostate cancer patients who either received the combination therapy of CAN-2409+prodrug (valacyclovir)+SOC or SOC alone. The study met its primary endpoint, demons ...